Pre-Made Omfiloctocog Alfa Biosimilar, Recombinant Protein targeting F8: Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-INN-934

Pre-Made Omfiloctocog Alfa Biosimilar, Recombinant Protein targeting F8: Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Omfiloctocog alfa is the first third-generation B-domain-deleted recombinant factor VIII. It is used to treat the hemophilia A

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-INN-934-1mg 1mg 3090
GMP-Bios-INN-934-10mg 10mg Inquiry
GMP-Bios-INN-934-100mg 100mg Inquiry
GMP-Bios-INN-934-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:

For more than 100mg, click here for inquiry. >>


Description

Products Name (INN Index) Pre-Made Omfiloctocog Alfa Biosimilar, Recombinant Protein targeting F8: Recombinant therapeutic protein targeting AHF/F8B/F8C/HEMA/FVIII/DXS1253E
INN Name Omfiloctocog Alfa
TargetF8
FormatRecombinant Protein
Derivationhuman
Species Reactivityhuman
CH1 IsotypeF8 (coagulation factor VIII) with deleted B-domain
VD LCF8 (coagulation factor VIII) with deleted B-domain
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
CompaniesSinocelltech Ltd. (Beijing China)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech0